IL267781A - Heterocyclic spiro compounds as magl inhibitors - Google Patents
Heterocyclic spiro compounds as magl inhibitorsInfo
- Publication number
- IL267781A IL267781A IL267781A IL26778119A IL267781A IL 267781 A IL267781 A IL 267781A IL 267781 A IL267781 A IL 267781A IL 26778119 A IL26778119 A IL 26778119A IL 267781 A IL267781 A IL 267781A
- Authority
- IL
- Israel
- Prior art keywords
- spiro compounds
- heterocyclic spiro
- magl inhibitors
- magl
- inhibitors
- Prior art date
Links
- -1 Heterocyclic spiro compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449242P | 2017-01-23 | 2017-01-23 | |
| PCT/IB2018/050128 WO2018134698A1 (en) | 2017-01-23 | 2018-01-09 | Heterocyclic spiro compounds as magl inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL267781A true IL267781A (en) | 2019-09-26 |
Family
ID=61028112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267781A IL267781A (en) | 2017-01-23 | 2019-07-01 | Heterocyclic spiro compounds as magl inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180208608A1 (https=) |
| EP (1) | EP3571202B1 (https=) |
| JP (1) | JP2020506903A (https=) |
| KR (1) | KR20190097242A (https=) |
| CN (1) | CN110198944A (https=) |
| AU (1) | AU2018208848A1 (https=) |
| BR (1) | BR112019014099A2 (https=) |
| CA (1) | CA3050853A1 (https=) |
| IL (1) | IL267781A (https=) |
| MX (1) | MX2019008690A (https=) |
| RU (1) | RU2726631C1 (https=) |
| SG (1) | SG11201906427QA (https=) |
| TW (1) | TWI665199B (https=) |
| WO (1) | WO2018134698A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA121775C2 (uk) | 2015-07-31 | 2020-07-27 | Пфайзер Інк. | 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl |
| WO2018005865A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
| EP3571191A1 (en) * | 2017-01-20 | 2019-11-27 | Pfizer Inc | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| MX2020007318A (es) * | 2017-09-29 | 2020-08-24 | Takeda Pharmaceuticals Co | Compuesto heterociclico. |
| US10662159B2 (en) * | 2017-11-22 | 2020-05-26 | Makscientific, Llc | ABHD6 and dual ABHD6/MGL inhibitors and their uses |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| AU2019304198A1 (en) * | 2018-07-19 | 2021-02-04 | Pfizer Inc. | Heterocyclic spiro compounds as MAGL inhibitors |
| AU2019325685B2 (en) | 2018-08-24 | 2025-07-24 | Pharmacosmos Holding A/S | Improved synthesis of 1,4-diazaspiro(5.5)undecan-3-one |
| KR20210069079A (ko) * | 2018-09-28 | 2021-06-10 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
| MY205440A (en) | 2018-09-28 | 2024-10-21 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| AU2019389017B2 (en) * | 2018-11-28 | 2025-01-09 | H. Lundbeck A/S | Methods of treating disease with MAGL inhibitors |
| CN109485656A (zh) * | 2018-12-17 | 2019-03-19 | 上海药明康德新药开发有限公司 | 3-氧亚基-7-氧杂-2,10-二氮杂螺[4.6]十一烷-10-甲酸叔丁酯的制法 |
| MA54827A (fr) * | 2019-01-25 | 2022-05-04 | H Lundbeck As | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl |
| CN114096545A (zh) * | 2019-07-09 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 新杂环化合物 |
| JP7697934B2 (ja) | 2019-09-30 | 2025-06-24 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射線標識されたｍｇｌ ｐｅｔリガンド |
| WO2021191391A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
| CN113966337B (zh) * | 2020-05-12 | 2024-01-02 | 北京广为医药科技有限公司 | 调节nmda受体活性的化合物、其药物组合物及用途 |
| MX2023003240A (es) * | 2020-09-22 | 2023-06-16 | Janssen Pharmaceutica Nv | Moduladores de monoacilglicerol lipasa de ciclobutilamida. |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| TWI904281B (zh) * | 2020-11-13 | 2025-11-11 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
| WO2022135462A1 (zh) * | 2020-12-22 | 2022-06-30 | 鲁南制药集团股份有限公司 | Magl抑制剂的医药用途 |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
| EP4665718A1 (en) | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273659A1 (en) | 1986-12-27 | 1988-07-06 | Takeda Chemical Industries, Ltd. | Azaspiro compounds, their production and use |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CA2195107A1 (en) | 1994-08-02 | 1996-02-15 | Richard Alexander Jelley | Azetidine, pyrrolidine and piperidine derivatives |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AU3676100A (en) | 1999-04-09 | 2000-11-14 | Mochida Pharmaceutical Co., Ltd. | Remedies for neuropathic pain |
| EP1209974A2 (en) | 1999-08-13 | 2002-06-05 | Aventis CropScience GmbH | Heterocyclic spiro compounds as pesticides |
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| DE60125980T2 (de) | 2000-11-20 | 2007-10-25 | Scios Inc., Sunnyvale | P38kinase-inhibitoren vom piperidin/piperazin-typ |
| CN1264847C (zh) | 2001-05-14 | 2006-07-19 | 弗·哈夫曼-拉罗切有限公司 | 1－氧杂－3,9－二氮杂－螺[5.5]十一－2－酮衍生物及其作为神经激肽受体拮抗剂的用途 |
| EP1622569B1 (en) | 2003-04-24 | 2015-12-02 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metallproteases |
| US7825147B2 (en) | 2003-08-29 | 2010-11-02 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
| SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| AR046756A1 (es) | 2003-12-12 | 2005-12-21 | Solvay Pharm Gmbh | Derivados de hidronopol como agonistas de receptores orl-1 humanos. |
| JP3912400B2 (ja) | 2004-03-30 | 2007-05-09 | 株式会社デンソー | 圧力センサ |
| ES2370788T3 (es) | 2005-02-07 | 2011-12-22 | Aerocrine Ab | Controlar flujo de aliento exhalado durante análisis. |
| EA013646B1 (ru) | 2005-05-25 | 2010-06-30 | Басф Акциенгезельшафт | Замещённые бензоилом серин-амиды |
| MX2007014490A (es) | 2005-05-25 | 2008-02-11 | Basf Ag | Serina amidas sustituidas con heteroaroilo. |
| MX2007016508A (es) | 2005-06-30 | 2008-03-04 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g. |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| EP2102208B1 (en) | 2006-12-05 | 2014-04-23 | Janssen Pharmaceutica NV | Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| CA2684633A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
| EP2058306A1 (en) | 2007-11-08 | 2009-05-13 | Schwarz Pharma Ag | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| MX2011004340A (es) | 2008-10-29 | 2011-05-23 | Gruenenthal Gmbh | Espiroaminas sustituidas. |
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| MX342128B (es) | 2008-12-24 | 2016-09-14 | Bial - Portela & C A S A | Compuestos farmaceuticos. |
| US8415341B2 (en) | 2009-04-22 | 2013-04-09 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| JP2012524800A (ja) | 2009-04-22 | 2012-10-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| JPWO2011142359A1 (ja) | 2010-05-10 | 2013-07-22 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| CA2810077A1 (en) | 2010-09-27 | 2012-04-05 | Peter J. Connolly | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors |
| BR112013009828A2 (pt) | 2010-10-22 | 2016-07-26 | Janssen Pharmaceutica Nv | diamidas de amino-pirrolidina-azetidina como inibidores de monoacilglicerol lipase |
| US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| CN103517910B (zh) | 2011-03-14 | 2016-12-14 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
| JP2014159376A (ja) | 2011-06-17 | 2014-09-04 | Taisho Pharmaceutical Co Ltd | アザスピロアルカン化合物 |
| US9487495B2 (en) * | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| WO2013131010A2 (en) | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2015104343A1 (en) | 2014-01-09 | 2015-07-16 | Proyecto De Biomedicina Cima, S.L. | New antifibrinolytic compounds |
| ES2878041T3 (es) * | 2015-03-18 | 2021-11-18 | H Lundbeck As | Carbamatos de piperazina y métodos para prepararlos y usarlos |
| UA121775C2 (uk) | 2015-07-31 | 2020-07-27 | Пфайзер Інк. | 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl |
| WO2017197192A1 (en) * | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
-
2018
- 2018-01-09 EP EP18701578.9A patent/EP3571202B1/en active Active
- 2018-01-09 RU RU2019123020A patent/RU2726631C1/ru active
- 2018-01-09 BR BR112019014099-9A patent/BR112019014099A2/pt not_active Application Discontinuation
- 2018-01-09 SG SG11201906427QA patent/SG11201906427QA/en unknown
- 2018-01-09 JP JP2019538585A patent/JP2020506903A/ja not_active Withdrawn
- 2018-01-09 CN CN201880007992.7A patent/CN110198944A/zh active Pending
- 2018-01-09 CA CA3050853A patent/CA3050853A1/en not_active Abandoned
- 2018-01-09 WO PCT/IB2018/050128 patent/WO2018134698A1/en not_active Ceased
- 2018-01-09 KR KR1020197021451A patent/KR20190097242A/ko not_active Withdrawn
- 2018-01-09 MX MX2019008690A patent/MX2019008690A/es unknown
- 2018-01-09 AU AU2018208848A patent/AU2018208848A1/en not_active Abandoned
- 2018-01-18 TW TW107101775A patent/TWI665199B/zh not_active IP Right Cessation
- 2018-01-22 US US15/876,698 patent/US20180208608A1/en not_active Abandoned
-
2019
- 2019-06-03 US US16/429,678 patent/US10858373B2/en active Active
- 2019-07-01 IL IL267781A patent/IL267781A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020506903A (ja) | 2020-03-05 |
| US10858373B2 (en) | 2020-12-08 |
| EP3571202A1 (en) | 2019-11-27 |
| EP3571202B1 (en) | 2021-06-30 |
| BR112019014099A2 (pt) | 2020-02-11 |
| WO2018134698A1 (en) | 2018-07-26 |
| AU2018208848A1 (en) | 2019-07-18 |
| TWI665199B (zh) | 2019-07-11 |
| US20180208608A1 (en) | 2018-07-26 |
| SG11201906427QA (en) | 2019-08-27 |
| CA3050853A1 (en) | 2018-07-26 |
| MX2019008690A (es) | 2019-09-18 |
| TW201838995A (zh) | 2018-11-01 |
| KR20190097242A (ko) | 2019-08-20 |
| US20190292203A1 (en) | 2019-09-26 |
| RU2726631C1 (ru) | 2020-07-15 |
| CN110198944A (zh) | 2019-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267781A (en) | Heterocyclic spiro compounds as magl inhibitors | |
| ZA202003778B (en) | Heterocyclic compounds as prmt5 inhibitors | |
| ZA201807249B (en) | Heterocyclic compound | |
| SG11202005112TA (en) | Heterocyclic compounds as prmt5 inhibitors | |
| ZA202003528B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| ZA201706710B (en) | Heterocyclic compounds as lsd1 inhibitors | |
| PT3371190T (pt) | Compostos heterocíclicos como inibidores de pi3k-gamma | |
| LT3498693T (lt) | Heterociklinis junginys | |
| HRP20221051T1 (hr) | Heterociklički spojevi kao inhibitori ret kinaze | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL282659A (en) | Heterocyclic compounds as bet inhibitors | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL254424A0 (en) | Disubstituted heterocyclic tricyclic compounds | |
| IL280292A (en) | Spiro-heterocyclic substances and their use as MAGL inhibitors | |
| PT3643718T (pt) | Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1 | |
| IL262448B (en) | Disubstituted heterocyclic bicyclic compounds | |
| IL254890A0 (en) | The tercyclic compound | |
| ZA201907792B (en) | Heterocyclic compound | |
| GB201806488D0 (en) | Heterocyclic TADF compounds | |
| ZA201907793B (en) | Heterocyclic compound | |
| GB201808580D0 (en) | Heterocyclic compounds |